A comprehensive view of Eye Care. This page highlights a small sample of our full coverage.
For real-time access, please log in to your Bioeconomy Market Intelligence Service.

Recent Articles

sample of recent headlines, press releases and get more..

FDA approves Lensar’s Ally Lensar cataract treatment system that combines femtosecond laser with phacoemulsification ultrasound technology; cataracts are world’s top cause of treatable blindness, cataract surgery most common surgical procedure in US
Published: June 21, 2022 by PR Web
Johnson & Johnson Vision to launch Acuvue OASYS MAX 1-Day, Acuvue OASYS MAX 1-Day Multifocal premium contact lens in US, Canada, Europe in autumn; 71% of eye care professionals say patients reporting eye comfort issues due to increased daily screen time
Published: June 17, 2022 by PR Newswire Europe
Bausch & Lomb launches Revive customizable soft contact lens in US that fit a wide range of patients, including those with high or unique prescriptions; non-ionic material allows lenses to be worn daily for up to three months
Published: June 16, 2022 by Canada StockWatch
Bausch + Lomb reports Q1 GAAP net income down at US$20.0M from US$27.0M a year ago, with revenue up 1% at US$889.0M; vision care sales up 1% from a year ago at US$560.0M, surgical up 7% to US$174.0M, ophthalmic pharmaceuticals down 5% to US$155.0M
Published: June 13, 2022 by Bausch & Lomb Inc.
Biogen and Samsung Bioepis announce July launch of Byooviz in US, a biosimilar of Roche’s injectable Lucentis, to treat wet age-related macular degeneration, macular edema. myopic choroidal neovascularization; drug priced 40% lower than Lucentis
Published: June 07, 2022 by FiercePharma

Ask us about our Bioeconomy market view

Trending Chart

Interactive chart with headline count